GENinCode Plc

Equities

GENI

GB00BL97B504

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:01 2024-05-23 am EDT			5-day change	1st Jan Change
8.25 ^GBX	0.00%		-5.71%	+57.14%

Apr. 04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
Mar. 21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

GENinCode raises GBP4 million via placing and subscription

December 21, 2023 at 04:56 pm EST

GENinCode PLC - biotechnology company focused on prevention of cardiovascular disease - Raises GBP4.0 million via a placing and subscription, announced earlier Thursday, at the issue price of 5 pence per share. The issue price represents a discount of 7.1% to the closing middle market price of 5.38p on December 20, the last business day prior to the announcement of the fundraising. The placing was undertaken through an accelerated bookbuild process. A further announcement will be made on December 28 announcing the result of the retail offer under which the company aims to raise up to GBP1.0 million via Bookbuild to existing retail shareholders.

Current stock price: 5.63 pence, closed 4.7% higher on Thursday

12-month change: down 34%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about GENinCode Plc

GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	Apr. 04	CI
GENinCode says ROCA recommended as ovarian cancer risk test in England	Mar. 21	AN
GENinCode gets GBP57,000 in retail offer, well below maximum	Dec. 28	AN
GENinCode Raises GBP4 Million from Share Sale	Dec. 28	MT
GENinCode raises GBP4 million via placing and subscription	Dec. 21	AN
Genincode Plc Announces Placing And Subscription To Raise A Minimum Of £4.0 Mln	Dec. 21	RE
Aura eyes Tiris expansion; Kavango backs Pambili	Nov. 29	AN
GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway	Nov. 29	CI
EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up	23-09-20	AN
Earnings Flash (GENI.L) GENINCODE Reports H1 Revenue GBP950,000	23-09-20	MT
Earnings Flash (GENI.L) GENINCODE Posts H1 Loss GBX-3.33	23-09-20	MT
GENinCode Plc Provides Revenue Guidance for the Second Half of 2023	23-09-20	CI
GENinCode Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease	23-08-30	CI
GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit	23-08-16	DJ
GENinCode Submits Premarket Notification for US Commercial Distribution of Polygenic Test Kit	23-08-16	MT
GENinCode plc Files its Premarket Notification with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease	23-08-16	CI
Certain Ordinary Shares of GENinCode Plc are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI
GENinCode Shares Rise Amid US Partnership with MedStar Health	23-07-19	MT
GENinCode and MedStar collaborate on coronary heart disease testing	23-07-19	AN
GENinCode Plc Announces Collaboration with MedStar Health	23-07-19	CI
GENinCode annual loss widens; focuses on US, EU, and NHS in UK	23-06-06	AN
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-06	CI
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-06	CI
GENinCode Plc Auditor Raises 'Going Concern' Doubt	23-06-04	CI

Chart GENinCode Plc

Duration

Period

More charts

Company Profile

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for GENinCode Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENINCODE PLC	+57.14%	18.58M
BIOMÉRIEUX	-5.86%	12.09B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.87%	8.21B
DIASORIN S.P.A.	+5.47%	5.74B
LANTHEUS HOLDINGS, INC.	+27.57%	5.64B
AUTOBIO DIAGNOSTICS CO., LTD.	-9.89%	4.16B
10X GENOMICS, INC.	-59.04%	2.88B
ANDON HEALTH CO., LTD.	+8.97%	2.69B
VITROLIFE AB	-5.19%	2.33B
MYRIAD GENETICS, INC.	+21.32%	2.17B

Diagnostic & Testing Substances